BACE1 and Alzheimer disease: Some composite AD therapy scenarios, described above in Section 25 (for conventional AD; see Figure 13, panel A) and Section 33 (for unconventional AD; see Figure 23), entail the long-term activation of BACE1 and/or BACE2 following the withdrawal of inhibitors of the integrated stress response, i.e., under ISR conditions.